Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

YEZTUGO

LENACAPAVIR SODIUM

Standard Dose
EQ 300MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview YEZTUGO is listed in Drugs@FDA under application 220020 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR SODIUM Form and strength TABLET;ORAL - EQ 300MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview YEZTUGO is listed in Drugs@FDA under application 220020 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient LENACAPAVIR SODIUM Form and strength TABLET;ORAL - EQ 300MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2025-06-18 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.